



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3273 9133
Facsimile: + 61 7 3375 1168
www.tbgbio.com

TBG Diagnostics and Omixon formalise Asia Pacific partnership for Holotype HLA Typing product distribution

Key highlights

- **TBG chosen by Omixon for distribution of world leading Next Gen Sequencing HLA typing product through Asia Pacific region**
- **Oximon Holotype HLA emerging global leader in HLA typing by NGS**
- **TBG and Oximon are completing a multi-site customer validation program**
- **Partnership to open up new distribution product pipeline for TBG**

Melbourne, Australia, 15 November 2016. The Board of TBG Diagnostics Limited (ASX: TDL, OTC: PGLA) (the **Company** or **TBG**) is pleased to announce an exclusive Distribution and Support Partnership for the Asia Pacific region, including China, Hong Kong, Taiwan and Australia. TBG will be the exclusive distributor of Omixon's world leading Holotype HLA products for HLA typing by NGS. Omixon, domiciled in Cambridge, Massachusetts, is a global leader in HLA typing product development and supplies accurate high-resolution HLA genotyping products to more than 20 hospitals worldwide.

The Holotype HLA is a combination Assay and Software product that leverages Next Generation Sequencing (NGS) and provides one of the most accurate high-resolution genotyping available. Working together with Omixon, TBG has added the Holotype HLA protocols to list of HLA typing solutions that can be automated by TBG's DX-A™ Automated Pipetting System. The DX-A™ can now be used to automate many HLA typing solutions including SSO, SBT and NGS.

TBG Diagnostics was chosen by Omixon due to TBG's strong presence in nearly all Asian Pacific markets and having the ability to integrate channels for Omixon's products to existing diagnostics customers.

Omixon Chief Executive Officer, Tim Hague said *"We are delighted to be working with such a highly skilled and motivated sales and technical support partner as TBG Diagnostics"*.

Chief Executive Officer of TBG Biotechnology Taiwan Chief Operating Officer, Eugene Cheng said: *"This strategic partnership between TBG and Omixon represents a significant opportunity for our company to continue our supply of innovative HLA solutions to the growing Asia Pacific market. We are very pleased that Omixon chose to partner with TBG due to our technical capabilities and channels to market. As this partnership develops, TBG will continue to grow our product lines into the vast molecular diagnostics market in China and the region."*

Investor Relations and Media Contact:

Peter Taylor
NWR Communications
+61 412 036 231
peter@nwrcommunications.com.au

About TBG Diagnostics

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020.

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases

About Omixon

Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon's flagship product, Holotype HLA™, is the world's leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide.

Omixon's research software, HLA Explore™ analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. www.omixon.com